Fermentas UAB
The company has been established in 1995 on the basis of one of production division of the institute of Biotechnology. Fermentas UAB is the greatest company in Lithuania and one of world's leading developers and producers of new molecular biology tools and molecular diagnostics products. Fermentas develops and produces high-quality essential components for molecular diagnostics such as ferments, nucleic acid standards, etc.

The company has 274 employees as of end of April, 2007. Key product groups produced by the company:
·                 Restriction endonucleases
·                 Nucleic acid modification enzymes
·                 Polymerase chain reaction (PCR) reagents
·                 DNA/RNA and protein markers
·                 Nucleotides
·                 Molecular biology kits
·                 Various reagents
Some products are produced by technologies patented by the company. These are: Nb.Bpu10I nicating endonuclease, Eco57MI restriction endonuclease, TrueStartTM Taq DNA Polymerase, cleanup of plasmid DNA to order, NoLimitsTM DNR marker production to order.

At the onset of 2007, the company was producing over 500 of different products 100 of which were produced by licence contracts. Currently there are 23 licence contracts concluded by the company. In 2006, the sales amounted to LTL 50.7 million, 99% of which was export; net profit: LTL 9.15 million; net profitability: 18%; productivity: LTL 219 thousand/employee; average number of employees on payroll: 231 as of the end of 2006.

Within the scope of common scientific research projects, the company collaborates with Vilnius and Kaunas Universities of Technology, Institutes of Biochemistry and Biotechnology as well as research laboratories at foreign universities and companies.
In 2004-2006, the company has performed four EU 6 General Framework projects aimed towards the development of biotechnology molecular tools and two EU SF financed projects (See Table 11 of the Annex 2).

To expand its share on perspective markets for molecular diagnostics products, the company has started a large investment project in 2004 with the purpose to furnish new production facilities compliant with Good Manufacturing Practice (GMP) requirements. It will allow a complete reorganisation of production of products used in PCR technology in compliance with GMP requirements in a few years and will open huge and rapidly increasing markets for molecular diagnostics products. The company's strategic goal is to become a leading producer and supplier of ready to use diagnostic kits and thus create and develop Lithuanian industry of molecular diagnostics kits. 

 Biomedicinos Tyrimų Centras UAB (Biomedical Research Centre)
The company has been founded in 2000. It has started from the diagnostics of contagious diseases by modern molecular biology methods based on PCR. The company is the initiator of molecular diagnostics research in Lithuania. Currently BRC is the largest supplier of diagnostic service by PCR method in Lithuania. It is the most modern private company in Lithuania involved in laboratory medical diagnostics. It uses cutting-edge study methods; its activities comply with international quality control standards.

Today the Centre also performs laboratory tests other than the detection of pathogenic microorganisms and viruses by PCR method, namely: hormone and cancer marker blood levels; general blood and urine tests; cytologic tests; serologic diagnostics of contagious diseases. State-of-art Hitachi detection system that is among the most popular in Europe is used at the Centre for allergy tests. Since 2004 the Centre has started cytogenetic tests (karyotyping and FISH). Since 2005 biological fatherhood and chimerism tests are performed based on molecular genetic investigations of polymorphous DNA marker domains. In 2006 the value of diagnostic kit export to Ukraine and Kazakhstan by BRC reached LTL 82 thousand.

Imunolita UAB
Imunolita, a research-business company, was established in April 2006. Its scientific potential is rooted in former employees of VU Institute of Immunology who have extensive experience in studies of modulation impact on immunopathological processes by stem cell secreted factors. The purpose of the company is the creation and development of cellular technologies and their implementation in the field of practical medicine. The company specializes in personalized therapy where the patient is treated with an individually tailored technology product and patient's own blood, stem or immune system cells are generally used.

The company has 10 employees. Imunolita UAB has been only recently established, therefore its economic metrics are not informative yet. The company has received a grant from the Ministry of Economics for the performance of project: New Technology for Multiple Sclerosis Treatment by Vaccination with Autologous T-Cells.

Sicor Biotech UAB
The origins of Sicor Biotech UAB are related to the programme of restructuring and privatisation of the Institute of Biotechnology carried out in 1994 that included founding of Biofa AB on the basis of one of production divisions of this Institute. In 1999, Sicor Biotech UAB (formerly Biotechna UAB) acquired the production facilities and technologies of Biofa biopharmaceutical company and employed its staff. In 2001, Sicor Biotech became a part of Sicor Inc. group (USA). Since the merger of Sicor Inc. and Israeli company Teva Pharmaceutical Inc. in 2004, Sicor Biotech UAB has become a leader of Teva Group biotechnology division.

Studies of protein pharmaceutical substances started in 1984 at the Institute of Applied Enzymology (now Institute of Biotechnology). Clinical trials were successfully completed and human recombinant interferon alpha-2b (Reaferon) created in Lithuania was registered in 1989. It was the first gene-engineered medical preparation developed in then USSR and the entire Eastern and Central Europe. This medication is designed to combat certain forms of cancer. It is worth noting that it was the sixth gene-engineered medication created in the world. Somatogen-L, a human growth hormone, was registered in Lithuania in 1994 and Grasalva, a modified granulocyte colony stimulating factor (GCSF), was registered in 2003.

The technologies built on scientific research have helped obtaining huge foreign investment sources. A modern universal plant for production of biotechnology preparations compliant with European, USA, and Lithuanian requirements for pharmaceutical production was built in Vilnius in 2000. Almost LTL 100 million invested in this plant falls among the largest greenfield investments ever in Lithuania.

Currently (as of 2007) the company has 141 employees. Sicor Biotech is distinguished by especially highly qualified staff: it includes almost 20 science doctors and about 80% of staff have special higher education. Currently the company have 27 employees having recently graduated in the field of bioengineering at Vilnius Gediminas Technical University. Sicor Biotech scientific division employs 35 high-class professionals involved in relevant technologies for biopharmaceutical products. This was one of key factors enabling Sicor Biotech technologies to compete on global pharmaceutical markets and produce high-quality medications. The quality of medications produced by this Lithuanian company successfully compete with equivalent medications produced by such well-known companies as F.Hoffmann-La Roche, Schering Plough, Eli Lilly and Novo Nordisk.

The key production of the company is active pharmaceutical substances, namely interferon alpha-2b, filgrastim, and human growth hormone and medical preparations Realdiron, Grasalva, and Biosoma produced on the basis of these substances. The following preparations are currently produced:
·                 Human recombinant interferon alpha-2b: Realdiron®; Realdiron Set®; Uniferon.
·                 Recombinant human growth hormone: Biosoma®.
·                 Filgrastim (r-metHuGCSF): Grasalva™.
Sicor Biotech is a holder of 9 Lithuanian patents, 5 of which are patents for currently manufactured products; 1 patents of manufactured products is registered in Russian Federation, 1 in Italy, 1 in Finland, and 1 in Canada.
Key metrics in 2006 were the following: sales amount: LTL 35.4 million; export: 65%; gross profit: LTL 18.9 million; gross profitability: 53.5 %; productivity: LTL 251 thousand/employee.

Biota UAB
Biota UAB was established in 1991, the company specialized in biotechnology R&D services. The company has 4 employees. Biotechnology research activities performed at the company are focused on recombinant protein purification and analysis of various proteins. The company uses a scientific laboratory on lease; its research activities are directed towards the fusion of biopharmaceutical, medical, proteomics, and bioinformatics fields.
In its scientific activities, Biota UAB collaborates with Vilnius University, the Institute of Biochemistry, and VU Institutes of Immunology and Oncology. A portion of R&D studies are performed at these institutions on order of the company.

Biotechpharma UAB
The company was established in 2004. Since its establishment, the company has been performing research tasks by order in the fields of proteomics and molecular biotechnology as well as biopharmaceutical analysis works. Since the beginning of 2007, the company has started an R&D project: Development of Technology for Biosynthesis and Recovery of Zymogenic Form of Serine Protease financed from EU SF (LTL 2.55 million). The purpose of this project is the development of commercially applicable technologies for protein biosynthesis and purification. There are plans for the development of a competitive technology for prourokinase production eliminating the need for organic solvents, with all stages performed in medium pressure columns, i.e. a technology available for licensing. The potential of such a technology would also stem from the ability of its application by a well-known biotech company such as Sicor Biotech capable of producing a product of required quality for clinical trials. A part of project budget (to 15%) will be spent on orders (scientific studies, analytical tasks, etc.) fulfilled by other Lithuanian scientific research institutions and business. During this project, the company plans to use a recombinant tissue culture technology licensed by a foreign company. After the project is complete, a development of commercially attractive know-how is planned.
Currently the company has 5 employees but this number is to be increased considering intensive development of the company.

Biocentras UAB
Biocentras research and production company was formed in 1988. The core workers were scientists from the Institute of Biotechnology with broad experience in resolving scientific and production issues in the area of biotechnological treatment of oil pollutants. At present the company has 28 workers including 8 with a doctoral degree.
The area of activities of Biocentras comprises the application of biotechnology processes in the environmental protection and professional services of oil pollutants‘ clean-up. In the latter field the company applies advanced, human- and environmentally-friendly biotechnology methods based on the use of natural microorganisms and enzymes produced from them. Other lines of work: biotechnological clean-up of environment contaminated with grease; search for and production of biologically active substances of microbiological origin; production and sale of sorbets and sorbet products; designing and construction of environmental projects (contaminated soil and water treatment sites, surface wastewater treatment facilities); treatment of sewage, highly contaminated industrial sewage and landfill filtrate.

The company‘s specialists take an active part in international research projects. Jointly with British, Italian, Spanish, Dutch, Portuguese and Latvian scientists they implement several projects under the 6th Framework Programme and EUREKA. Most employees of the company are holders of qualifications certificates entitling to design environmental projects and to conduct project supervision. Scientists from Biocentras deliver a course on ecological biotechnology at VGTU and participate in the delivery of master’ studies; one employee has prepared and defended a doctoral thesis.

Malsena AB
Malsena AB has put into operation a high-capacity wheat starch plant; the estimated production volume for 2010 is 105,000 tons per year. The larger part of the high-quality Type A starch will be modified into cationic starch, while Type B starch, which is not fit for paper industry, will be transformed into valuable technical products (glue, bioplastics or biofuel components) by chemical and biotechnological methods.

Achema Group
The Achema Group is a trust with a strong financial position, which searches for new areas of activities with good prospects. Biotechnology is one of such areas. The Trust has broad experience in the use of chemical technologies in production and is preparing projects on the production of a new polymer – polylactic acid. The product will be intended for the production of rapidly degrading (biodegradable) packaging.

Profarma UAB
A spin-off company established by the Institute of Biotechnology in 2007, just starting its business activities.